



MARKET RELEASE

30 March 2017

Opthea Limited

TRADING HALT

The securities of Opthea Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Monday, 3 April 2017 or when the announcement is released to the market.

Security Code: OPT

Kobe Li

SENIOR ADVISER, LISTINGS COMPLIANCE (MELBOURNE)



30 March 2017

Kobe Zheng Li
Senior Advisor, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
Level 4, Rialto North Tower
525 Collins Street
Melbourne VIC 3000

By email: zheng.li@asx.com.au
james.gerraty@asx.com.au
tradinghaltsmelbourne@asx.com.au

Dear Kobe

Opthea Limited (ASX: OPT)

Request for Trading Halt

Pursuant to Listing Rule 17.1, Opthea Limited (ACN 006 340 567) (**Opthea**) requests an immediate trading halt in all of its quoted securities (ASX Code: OPT), pending the release of an announcement in relation to the results of Opthea's wet AMD phase 1/2A clinical trial and a potential capital raising.

Opthea requests that the trading halt remain in place prior to the commencement of trading on Monday, 3 April 2017.

Opthea is not aware of any reason why the trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely

A handwritten signature in black ink, appearing to read "Mike Tonroe", followed by a horizontal line extending to the right.

Mike Tonroe
Company Secretary